Infectious endophthalmitis after intravitreal injection of antiangiogenic agents.
about
Exogenous endophthalmitis in diabetic patients: a systemic reviewBacterial endophthalmitis in the age of outpatient intravitreal therapies and cataract surgeries: host-microbe interactions in intraocular infectionPotential penetration of topical ranibizumab (Lucentis) in the rabbit eye.Toll-like receptor 2 ligand-induced protection against bacterial endophthalmitisComparative cyto-histological study of needle tip aspirates and entry sites after intravitreal injection using different needle types.Endophthalmitis: state of the art.Nanosponge-Mediated Drug Delivery Lowers Intraocular Pressure.Comparison of the short-term effects of intravitreal triamcinolone acetonide and bevacizumab injection for diabetic macular edema.Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degenerationOne-Year Feasibility Study of Replenish MicroPump for Intravitreal Drug Delivery: A Pilot Study.Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate.Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes.Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.A European perspective on topical ophthalmic antibiotics: current and evolving options.Muller glia in retinal innate immunity: a perspective on their roles in endophthalmitis.Development of a novel disposable lid speculum with a drape.Antibacterial responses of retinal Müller glia: production of antimicrobial peptides, oxidative burst and phagocytosis.Clinical safety of ranibizumab in age-related macular degeneration.Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitis.Endophthalmitis following intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration.Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.Suspected bacterial endophthalmitis following intravitreal anti-VEGF injection: case series and literature review.Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literatureModeling intraocular bacterial infections.Safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents.A Large Outbreak of Fulminant Bacterial Endophthalmitis after Intravitreal Injection of Counterfeit Bevacizumab.Incidence and clinical features of post-injection endophthalmitis according to diagnosis.Study of the Acute Effects of Povidone-Iodine on Conjunctival Bacterial FloraBilateral same-session intravitreal injections of anti-vascular endothelial growth factors.Safety study of 38,503 intravitreal ranibizumab injections performed mainly by physicians in training and nurses in a hospital setting.Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask.Bacterial contamination of needles used for intravitreal injections: comparison between 27-gauge and 30-gauge needles.Bacterial contamination of needles used for intravitreal injections: a prospective, multicenter study.EGHB010, a Standardized Extract of Paeoniae Radix and Glycyrrhizae Radix, Inhibits VEGF-Induced Tube Formation In Vitro and Retinal Vascular Leakage and Choroidal Neovascularization In Vivo.Cinidium officinale and its Bioactive Compound, Butylidenephthalide, Inhibit Laser-Induced Choroidal Neovascularization in a Rat Model.Aster koraiensis Extract and Chlorogenic Acid Inhibit Retinal Angiogenesis in a Mouse Model of Oxygen-Induced Retinopathy.
P2860
Q26859314-842CDD2F-3995-4E84-808A-EDC556338759Q26998053-DE8C5520-1D52-4A06-BB48-42D3A1BDC225Q30424219-BEE1E1D4-F7E9-4073-9422-0BDC196931C4Q33556991-193A0FCB-8CD8-422F-999D-F559A4EB3DFAQ33887880-A9D77F11-9F7B-4C26-A161-B49973051D0AQ34952098-FA426223-A119-4035-9892-26C8F627C53BQ34953629-782FA548-929E-4723-8361-EC6FB49F8AB3Q35009731-E8966AF7-A984-406C-933B-21C545C31207Q35127099-1568C156-5BF4-42E9-A992-A54D1FA5E0DBQ35167647-F6684CEB-1529-4686-A9EE-369BC52D51DDQ35693314-D9EF30B3-D21A-4D9D-AC21-405629175E20Q36468197-15D85BCF-C9E1-4A53-A86E-958083286369Q36762577-A727D157-A9D2-4957-B7D1-DC8D076491FAQ36867161-FECCDB05-D3A8-4E55-B5F3-A50FC27B3AE7Q36971794-A483F6A4-74BE-436D-AF72-726ACB39CC4BQ37089290-8ED44C40-F19C-4A96-BB04-DB88B46350CDQ37607511-E6483A88-52C2-4338-AAAF-1CAC4F03B549Q37650580-9363F16A-B9DD-4BD3-B5B8-354557AFB864Q37763847-C083DBE5-98B7-4B35-93AD-757F312E21EBQ37879167-AED915B0-C335-4F91-AEA6-A7B8A1E2B08DQ37910660-8B716951-7C48-4A78-BE07-C43AED07FC2BQ38026388-6672FB80-42D2-40D7-ABA5-07F0533AC385Q38110731-920275A0-CBE2-4343-827B-32BCFFDB9084Q38827899-F9141E9F-09DC-4BD5-8B91-613D2F40188CQ38959185-CF27F1E8-CE13-472B-9449-93DF850010E7Q40625734-649104B6-FC81-4853-911B-203100FD391DQ40903779-D9D773B6-1E5A-4359-B892-DFA225B1D652Q41044420-5791BB1B-5A6E-45DD-89A7-489FF4C0A48DQ41649671-8DFBE0B5-3CCF-4C2D-A940-91D04FE6E07EQ41658197-AC1D1463-B9A3-46F3-99B6-AD176D999002Q42276004-230A6A9F-F378-4BE8-AAFD-F704CD618CBCQ43682547-11A00B49-D2BB-41B8-9974-5EA9848FFB73Q46211373-76FE34A1-0B83-4B2A-AF4A-45A67577ADA6Q47758215-9B914463-6845-4166-A83E-794060C9C235Q51628495-BB897AA1-2367-4FFC-8A6E-499462776E19Q55018025-5D154F07-46C1-4D96-9088-841B19B06309
P2860
Infectious endophthalmitis after intravitreal injection of antiangiogenic agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Infectious endophthalmitis after intravitreal injection of antiangiogenic agents.
@en
Infectious endophthalmitis after intravitreal injection of antiangiogenic agents.
@nl
type
label
Infectious endophthalmitis after intravitreal injection of antiangiogenic agents.
@en
Infectious endophthalmitis after intravitreal injection of antiangiogenic agents.
@nl
prefLabel
Infectious endophthalmitis after intravitreal injection of antiangiogenic agents.
@en
Infectious endophthalmitis after intravitreal injection of antiangiogenic agents.
@nl
P2093
P1433
P1476
Infectious endophthalmitis after intravitreal injection of antiangiogenic agents.
@en
P2093
Albert O Edwards
Colin A McCannel
John M Pach
Jose S Pulido
Sophie J Bakri
Teresa Diago
P304
P356
10.1097/IAE.0B013E31819D2591
P577
2009-05-01T00:00:00Z